Willebrand Starsi

Download as pdf or txt
Download as pdf or txt
You are on page 1of 23

American Society of Hematology

2021 L Street NW, Suite 900,


Washington, DC 20036
Phone: 202-776-0544 | Fax 202-776-0545
editorial@hematology.org

How I treat von Willebrand disorders in the elderly


Tracking no: BLD-2022-018534-CR1

Jacqueline Poston (University of Vermont, United States) Rebecca Kruse-Jarres (University of


Washington, United States)

Abstract:
Von Willebrand disease (VWD) is the most common bleeding disorders and especially milder type 1 VWD
might not be cared for in specialty clinics. Von Willebrand factor (VWF) levels rise with age, but
the rise of these levels do not necessarily correlate with bleeding risk. A recent bleeding history
combined with recent labs are important for hemostatic management decision during surgical
interventions. Antifibrinolytics appear safe in the elderly population, while DDAVP should be used
cautiously. Where needed, factor concentrates present a great treatment option.
Acquired von Willebrand syndrome (AVWS) is vastly underrecognized, but likely to surface in the
aging, especially in the setting of co-morbidities such as plasma cell dyscrasias. IVIG can be an
effective treatment in this scenario, but potentially increases thrombotic risk.

Conflict of interest: COI declared - see note

COI notes: JNP is a paid consultant for TeraImmune RKJ has been a paid consultant for Biomarin,
Pfizer and Genentech/Roche, has been an educational speaker for Genentech/Roche and Takeda and is
receiving research funding from Genentech.

Preprint server: No;

Author contributions and disclosures: J.P and R.K-J co-wrote this publication

Non-author contributions and disclosures: No;

Agreement to Share Publication-Related Data and Data Sharing Statement:

Clinical trial registration information (if any):


How I treat von Willebrand disorders in the elderly

Jacqueline N Poston1,2, Rebecca Kruse-Jarres3,4

Affiliations:
1. Division of Hematology/Oncology, Department of Medicine, Larner College of Medicine at the
University of Vermont, Burlington, VT
2. Division of Clinical Pathology, Department of Medicine, Larner College of Medicine at the
University of Vermont, Burlington, VT
3. Washington Center for Bleeding Disorders, Seattle, WA
4. Division of Hematology, Department of Medicine, University of Washington, Seattle, WA

Corresponding Author:
Rebecca Kruse-Jarres, MD, MPH
701 Pike Str., Ste 1900
Seattle, WA 98101
rkj@wacbd.org

Conflicts of Interest:

JNP is a paid consultant for TeraImmune


RKJ has been a paid consultant for Biomarin, Pfizer and Genentech/Roche, has been an
educational speaker for Genentech/Roche and Takeda and is receiving research funding from
Genentech.
Abstract

Von Willebrand disease (VWD) is the most common bleeding disorders and especially milder
type 1 VWD might not be cared for in specialty clinics. Von Willebrand factor (VWF) levels rise
with age, but the rise of these levels do not necessarily correlate with bleeding risk. A recent
bleeding history combined with recent labs are important for hemostatic management decision
during surgical interventions. Antifibrinolytics appear safe in the elderly population, while
DDAVP should be used cautiously. Where needed, factor concentrates present a great
treatment option.
Acquired von Willebrand syndrome (AVWS) is vastly underrecognized, but likely to surface in
the aging, especially in the setting of co-morbidities such as plasma cell dyscrasias. IVIG can be
an effective treatment in this scenario, but potentially increases thrombotic risk.
I. Introduction

Managing inherited and acquired bleeding disorders in older patients (age > 65 years) requires
a holistic approach that incorporates each patient’s underlying comorbidities and risk factors
for treatment related complications. Von Willebrand disease (VWD) is the most prevalent
inherited bleeding disorder (0.8-1%)(1, 2) and most patients with milder disease are likely not
receiving care in specialty bleeding disorder center.(3) Acquired von Willebrand syndrome
(AVWS) is associated with lympho- or myeloproliferative disorders, solid tumors, autoimmune
disorders and conditions altering cardiac circulation. It is likely underreported and recognized
increasingly with advancing age of the patient. (4) Herein, we highlight things to consider when
caring for an older patient with a congenital or acquired von Willebrand disorder.

II. Case based discussion

Case One: Managing type 1 VWD in an older patient

A 77-year-old woman with type 1 VWD, hypertension and osteoarthritis presents for
preoperative recommendations for a hip replacement. She was diagnosed with type 1 VWD in
her early twenties when her von Willebrand factor (VWF) antigen (VWF:Ag) was 27 IU/dL and
her VWF ristocetin cofactor activity (VWF:RCo) was 29 IU/dL. She has a remote history of
bleeding consistent with type 1 VWD including epistaxis in childhood that was successfully
treated with cauterization and desmopressin (DDAVP), as well as heavy menstrual bleeding that
improved after starting combined oral contraception. In the last several years, she has not had
atypical bleeding such as prolonged epistaxis or easy bruising. She underwent laparoscopic
cholecystectomy 5 years ago without hemostatic prophylaxis and had no abnormal bleeding.
Her last documented VWF levels were when she was 42 years old with a VWF:Ag of 42 IU/dL
and VWF:RCo of 44 IU/dL.

Impact of aging on clotting factors


Coagulation factor activities, including VWF, are anticipated to change with age (Table 1). Both
VWF:Ag and VWF:RCo increase significantly with age in people without VWD(5), especially in
those who are not blood group O. (5, 6) In healthy cohorts, rising VWF levels and activities have
been associated with increased thrombogenicity. A longitudinal follow up of patients with type
1 VWD observed a similar increase and suggests that 20 to 50% of patients develop normalized
VWF:RCo (>50 IU/dL) with age.(7) A study of 31 patients with type 1 VWD showed an increase
in VWF:Ag and VWF:RCo over time with 58% of patients having normalization of both VWF:Ag
and VWF:RCo to ≥50 IU/dL, but also noted that not everyone experienced this increase. (7) A
larger study of 195 patients with type 1 VWD showed that this increase was mainly in those
with mild type 1 VWD (baseline VWF:Ag and VWF:RCo >30 to <50 IU/dL).(8) The rate of change
in the VWF:Ag and VWF:RCo does not appear to be impacted by sex. Although VWF:Ag and
VWF:RCo increase with age in type 1 VWD, the bleeding phenotype does not necessarily
improve. (9) It remains essential to quantify each patient’s bleeding score as symptoms are the
strongest predictor of outcomes and inversely correlate with VWF:Ag and VWF:RCo,
irrespective of age, sex and blood group.(10)

The rise in VWF levels with aging may be related to an increase in inflammation and underlying
comorbidities as VWF is an acute phase reactant; in the WiN study of 333 patients with type 1
VWD, the association between aging and rising VWF was not present after adjusting for
comorbidities.(11) It is also possible that the underlying mutation driving VWD impacts whether
VWF levels are responsive to age and inflammation as VWF levels appear to be minimally
impacted by aging in forms of type 2 VWD. (12)

Case One Continued


For surgical planning it is important to consider current rather than historical clotting factor
activities and to assess a recent bleeding history. Prior to formulating a treatment plan for her
hip replacement, this patient’s repeat VWF:Ag, VWF:RCo and factor VIII (FVIII) were 65 IU/dL,
64 IU/dL and 90 IU/dL, respectively. She asks whether she should receive DDAVP prior to
surgery given her positive experience with it in the remote past.

Does age impact treatment decisions for VWD?

Desmopressin (DDAVP)
DDAVP increases endogenous VWF levels transiently and can result in hyponatremia and
tachyphylaxis with ongoing use regardless of the age of the patient. Due to these limitations,
alternative hemostatic agents such as VWF factor products are favored following procedures
that require higher VWF levels for hemostatic control beyond the initial perioperative period
(>24-48 hours). This is particularly important in patients that require longer healing times due
to advanced age and/or underlying comorbidities.

In general, the use of DDAVP is not favored in older patients with VWD or mild hemophilia A
because of a theoretical increased risk for adverse events. Careful consideration must be given
to the patient’s comorbidities and sensitivity to fluid shifts and risk for seizure. Theoretically,
DDAVP may increase the risk of thrombosis in older patients especially in the setting of a rising
FVIII levels, however there is minimal data available to support this theoretical concern. Case
reports have documented arterial thrombotic events following DDAVP infusion, but these
events occurred in patients with strong underlying risk factors. (13-15) DDAVP has not been
shown to increase the risk of venous or arterial thrombosis in populations without bleeding
disorders at high risks for thrombotic events such as in the perioperative setting, as well as
following intracranial hemorrhage while on antiplatelet therapy(16) or with concurrent alcohol
abuse(17). Until more data is available in older patients with bleeding disorders, DDAVP should
be used cautiously particularly in the setting of elevated baseline FVIII levels, underlying cardiac
risk factors, or sensitive to fluid shifts.

Antifibrinolytics
Although there are limited data on the use of antifibrinolytics in older patients with bleeding
disorders, there are significant safety data showing no increased risk of thrombosis in older
patients without bleeding disorders including in the setting of traumatic injuries(18),
orthopedic(19-21) and cardiac surgeries(22). A meta-analysis of over 40,000 non-surgical
patients showed no increased risk of thrombosis, including stroke, myocardial infarction,
pulmonary embolism and deep vein thrombosis with tranexamic acid.(23) Notably, patients
without bleeding disorders typically receive antifibrinolytics for shorter durations, but a recent
trial of patients with hematologic malignancies did not show an increased risk of thrombosis
after an average of two weeks of tranexamic acid.(24) Given the available extensive and
reassuring safety data that included older populations, antifibrinolytics are an excellent option
for older patients with bleeding disorders.

VWF Clotting Factor Concentrates


The indications for VWF replacement concentrates and target VWF:RCo activity for major and
minor surgeries have been previously described.(25) Several plasma derived (also contain FVIII)
and one recombinant (does not contain FVIII) von Willebrand factor concentrate are available in
the United States (Table 2). In theory, the recombinant product may be a safer hemostatic
agent in an older patient with type 1 VWD if baseline FVIII levels are normal or increased,
because the product does not provide external FVIII. However, the exogenous VWF from rVWF
will stabilize and potentially further increase endogenous FVIII. Regardless of the product
selected, VWF and FVIII monitoring is necessary to gauge response. There are no studies
comparing VWF products in older patients with VWD and limited data on the risk of thrombosis
with plasma derived VWF products are available.

Case One Continued


Given the patient’s lack of recent bleeding symptoms and normalized levels of VWF:Ag,
VWF:RCo and FVIII with aging, the patient was prescribed no additional hemostatic agents
besides tranexamic acid following her hip replacement. She was also advised to discontinue
any drugs or supplements that could impact platelet function in the two weeks preceding
surgery and to limit the use of nonsteroidal anti-inflammatory drugs post-operatively. She
underwent hip replacement without any atypical bleeding or adverse event.

The 2021 combined guidelines on VWD from ISTH, ASH and WFH suggest “reconsidering” rather
than removing a diagnosis of type 1 VWD when VWF levels rise with age, especially since the
correlation between rising VWF levels and risk of bleeding has not been established.(26) In the
absence of bleeding symptoms the decision to reconsider or remove the diagnosis of VWD for
this patient should be considered and should be one of shared decision-making as per the 2021
ISTH, ASH and WFH combined guidelines.

Role of postoperative thromboprophylaxis


The decision to use medical thromboprophylaxis depends on the patient’s bleeding and clotting
history, VWF levels and risk for thrombosis of the procedure. For many patients with VWD, the
bleeding risk from medical thromboprophylaxis outweighs any benefit. Prophylactic
anticoagulation may be useful following higher risk surgeries for patients with low bleeding
scores whose VWF levels have normalized with aging. In our practice, we do not use
postoperative prophylactic anticoagulation for patients with bleeding disorders unless they
have negligible bleeding scores and normalized VWF levels with aging (similar to the patient in
case one). If prophylactic anticoagulation is used, the patient should be closely monitored for
bleeding symptoms with a low threshold to discontinue anticoagulation.

II. Case Two: Thrombotic event following intravenous immunoglobulin (IVIG) for acquired von
Willebrand syndrome (AVWS)

A 72-year-old man with obesity and AL amyloidosis complicated by cardiomyopathy and chronic
renal insufficiency on maintenance daratumumab presented with hematochezia after
undergoing biopsies during a colonoscopy. He denied any abnormal bleeding earlier in life but
had noticed increased bruising over the last year. Coagulation testing revealed a prolonged
activated partial thromboplastin time (aPTT) of 50s (reference range 26-37s) with a normal
prothrombin time (PT) and fibrinogen. Subsequent testing showed normal coagulation factors
except for a FVIII of 13 IU/dL, VWF:Ag of 10 IU/dL and a VWF:RCo below the limit of detection.
A pharmacokinetic study receiving a 100% corrective dose of a plasma derived VWF:FVIII
concentrate showed initial increase of VWF:Ag and RCo, but a significantly decreased half-life
(Figure 1) and he was diagnosed with acquired von Willebrand syndrome (AVWS).

The patient received 500 mg/kg of intravenous immunoglobulin (IVIG) with subsequent
normalization of his VWF:Ag, VWF:RCo and FVIII (Figure 2). Repeat colonoscopy showed
bleeding at the site of prior biopsies, which resolved after receiving IVIG. The patient was
discharged and continued to require IVIG once per month.. In retrospect, the patient had
increased bruising and an elevated aPTT for at least two years prior to diagnosis of AVWS.

Acquired von Willebrand syndrome


Acquired bleeding disorders are more common in older patients and should be considered
when patients present with new atypical bleeding and/or abnormal coagulation testing (Table
3). Most patients with amyloidosis who develop an acquired bleeding disorder have factor X
deficiency(27), but AVWS and acquired hemophilia A (AHA) can occur and should be considered
especially in the setting of an isolated prolongation in the aPTT.

Our patient presented with gastrointestinal bleeding, which may be more common in cases of
AVWS secondary to plasma cell dyscrasias based on an international registry(28) of patients
with AVWS from multiple causes including from mechanical destruction of VWF with loss of
high molecular weight multimers and altered clearance in the setting of aortic valve stenosis,
mitral valve regurgitation, and left ventricular assist devices.(4) In some cases, AVWS will
resolve with treatment of the underlying disease such as following valve replacement.(29, 30)
In patients with underlying plasma cell dyscrasias, autoantibodies increase clearance of VWF
and can persist despite adequate treatment of the plasma cell dyscrasia. VWF containing
concentrates and DDAVP are only transiently effective (return to baseline within 4 hours), but
intravenous immunoglobulin (IVIG) can lead to more sustained VWF levels (peak at 4 days and
return to baseline in 21 days) in AVWS from plasma cell dyscrasias. (31) This seems to be more
reliable in AVWS related to IgG monoclonal gammopathy of unknown significance (MGUS) over
IgM MGUS, where responses to IVIG have been varied.(31, 32) IVIG can be given 3-4 days prior
to surgery (suggested dose of 1 g/kg/day for 2 days) or can be given every 3 weeks (suggested
dose 1g/kg) to sustain chronic higher VWF levels to prevent bleeding. In our experience, doses
and dose intervals can be titrated to response. Thalidomide (33) and
lenalidomide/dexamethasone (34) have been used successfully to treat gastrointestinal
bleeding in AVWS. Rituximab has been used with inconsistent response. (35, 36)

Case Two Continued


The patient received IVIG 1 mg/kg every 3 weeks (see figure 3).

Approximately one year after diagnosis of AVWS, his IVIG dose was increased to 1.5 g/kg in an
attempt to increase his nadir VWF:RCo. Shortly thereafter, he represented with a sub-massive
pulmonary embolism (acute onset dyspnea and chest pain) two days after receiving IVIG. His
FVIII was 314 IU/dL four days prior to the thrombotic event. The patient also reported
decreased mobility over the prior year related to chronic knee and back osteoarthritis. He was
started on a heparin drip and bridged to warfarin with a goal INR of 2-3. Warfarin was selected
given the patient’s renal insufficiency and risk of acute bleeding if his VWF:RCo were to decline
while on anticoagulation. His IVIG dose was switched to twice per month instead of monthly
and was reduced to 0.2 g/kg to maintain lowest (nadir) VWF:RCo at or above 30 IU/dL while
avoiding "overshooting" FVIII above 200 IU/dL after redosing IVIG.

Risk of IVIG and Thrombosis


The risk of thrombosis with IVIG is unknown. Literature to date has reported a 0.5 to 17% rate
of arterial and venous thrombosis with IVIG.(37) One of the largest studies found a thrombosis
rate of 1-2% based on medical claims data for a retrospective cohort of 11,785 patients treated
with IVIG.(38) This study identified that thrombotic events were most likely to occur within 24
hours of IVIG use with the highest rates of thrombosis in patients over 45 years old and/or with
pre-existing hypercoagulable state. Subcutaneous immunoglobulin (vivaglobin) appeared to
carry a higher risk for thrombosis compared to intravenous immunoglobulin. In the experience
of the UK Biobank of patients receiving IVIG, 14,794 of 502,492 (2.9%) had a thromboembolic
event with the highest risk occurring in individuals with a prior history of thrombosis. (39) A
meta-analysis of 4129 patients in 31 randomized controlled trials of IVIG suggested IVIG does
not increase the risk of arterial and venous thrombosis, however the study population in this
meta-analysis was younger (median age 47) and may have been at lower risk for thrombosis.(37)
Other risk factors for thrombosis with IVIG identified in the literature include faster infusion
rates, higher doses of IVIG, atherosclerosis, IVIG use for autoimmune disorders (especially ITP),
and potentially higher levels of factor XI in the IVIG formulation.(38-42) It is unclear if medical
thromboprophylaxis reduces the risk of thrombosis from IVIG.
Other potential adverse events from IVIG include immediate infusion reaction (e.g., flushing,
fever, fatigue, chills, rash, hypotension, arrhythmia) and delayed infusion reactions (e.g.,
transfusion-related lung injury, hemolysis), rare neurological complications such as posterior
reversible encephalopathy syndrome, and renal dysfunction.(40) The risk of renal injury from
IVIG is highest in older patients, as well as those with diabetes mellitus, preexisting renal
dysfunction or dehydration. (40, 43)

Case Two Continued


After 3 months of therapeutic (INR 1.9-3.0) anticoagulation with warfarin, the patient
presented with a persistent bleed from a traumatic skin wound on his thigh, as well as 3 days of
dark stools. His INR was 5.0, VWF:RCo of 45 IU/dL and factor VIII activity of 86 IU/dL. Warfarin
was reversed with oral vitamin K and he received a low dose of IVIG 0.1g/kg with resolution of
his bleeding. The patient reported that he recently starting a new diet pill that contained
multiple supplements with potential interactions with warfarin. After his INR decreased to < 2,
the patient was transitioned to apixaban 2.5 mg by mouth twice daily for secondary prevention
of a venous thromboembolism. IVIG was continued at 0.2g/kg every two weeks.

III. Case Three: Managing antiplatelet therapy in a patient with type 1 VWD and coronary
artery disease
An 82-year-old man with type 1 VWD, hyperlipidemia, tobacco use and insulin dependent
diabetes mellitus presented with acute onset chest pain with an elevated troponin and
electrocardiogram changes consistent with an acute ST elevation myocardial infarction. At
baseline, the patient experienced easy bruising, intermittent epistaxis and bleeding following
surgery and trauma. His most recent VWF:RCo was 32 IU/dL, VWF:Ag 30 IU/dL and FVIII of 65
IU/dL. Prior to undergoing left heart catheterization, the patient received a VWF factor product
to achieve VWF:RCo >50 IU/dL. Catheterization revealed a left anterior descending (LAD)
infarction requiring angioplasty and stent placement. The cardiologist asks whether the patient
may receive dual antiplatelet therapy for one year.

Managing antiplatelet therapy


VWD may be protective against coronary artery disease.(44) However, although rare, coronary
artery disease requiring antiplatelet therapy can occur. In our practice, we aim to achieve a
VWF:RCo >50 IU/dL prior to catheterization and in the subsequent 24 to 48 hours. Ideally, close
communication between interventional cardiology and hematology occurs to discuss the choice
of stent and duration of anticoagulation. There is no data to guide which stent to select in this
patient population and limited case reports(45) suggest patients with VWD can fare well with
both bare metal and drug eluting stents. While current practice patterns for patients without
bleeding disorders favor dual antiplatelet therapy for at least one year after stent placement,
we discuss switching to single agent antiplatelet therapy with our cardiology colleagues as soon
as feasible in patients with bleeding disorders. There is no data on the goal VWF activity while
on antiplatelet therapy. We closely monitor patients for bleeding symptoms and consider using
concurrent VWF product prophylaxis, if concerning bleeding symptoms occur.
IV. Conclusion

Treatment of elderly patients with acquired or congenital von Willebrand disorders should be
tailored to each individual and incorporate the patient’s comorbidities and treatment
preferences. Some risk factors for adverse events from hemostatic therapies increase with age,
such as the risk of thrombosis due to rising clotting factors. Other side effects may also be more
common with advanced age, such as the risk of seizures and inability to tolerate fluid shifts with
DDAVP for older patients with mild hemophilia A, VWD, or AVWS. Acquired bleeding disorders
should also be considered for older patients present with new bleeding and/or coagulation
abnormalities.
Table 1: Changes in Coagulation Factors with Age
Clotting Factor Changes with Aging
Fibrinogen Increases(46, 47)
Thrombin Unaffected
FV Increases(48)
FX Unaffected
FVII Increases(46, 48)
FVIII Increases(46)
FIX Increases(48)
FXI Increases(48)
FXII Depends on the reference (unaffected vs increases)
FXIII Increases(49)
VWF VWF Ag increases with age, especially in those that are blood type Non-O(5, 6, 50)
Protein C Protein C Ag increases with aging (~4% by decade); in women this is primarily seen
after menopause(51)
Protein S Increases with age; lower and more variable increase in women due to increased
total protein S but no change in free protein S (increase in C4b-BP levels with
normal aging); may be impacted by serum lipids (higher protein S a/w higher
cholesterol and triglyceride levels)(52, 53)
PAI-1 Increases (especially in association with myocardial infarction, obesity and insulin
resistance, atherosclerosis, malignancy, inflammation and psychological stress)(54)
D Dimer Increases (especially in association with comorbidities such as infection, heart
disease and malignancy)(55)
Platelet count Decreased (more pronounced in males)(56)
Platelet Increases(57)
Activation
Bleeding time Shortens(57)
Table 2: VWF Products licenses to treat VWD in the U.S.
Product Indication Dosage (adults)* Approximate Reference
VWF:RCo:
FVIII ratio in
vial
Plasma derived
Alphanate Surgical and/or invasive Pre-operative 1.2:1 (58, 59)
procedures in adult and dose of 60 IU
pediatric patients with VWF:RCo/kg body
von Willebrand Disease weight;
in whom desmopressin subsequent doses
(DDAVP) is either of 40-60 IU
ineffective or VWF:RCo/kg body
contraindicated. It is not weight.
indicated for patients
with severe VWD (Type
3) undergoing major
surgery
Humate P (1)Treatment of (Target peak 2.4:1 (60, 61)
spontaneous and plasma VWF:RCo
trauma-induced bleeding level – baseline
episodes, and (2) plasma VWF:RCo
Prevention of excessive level)/in vivo
bleeding during and after recovery in patient
surgery. This applies to x body weight
patients with severe (BW) in kg
VWD as well as patients
with mild to moderate
VWD where the use of
desmopressin is known
or suspected to be
inadequate
Wilate (1) On-demand Required IU = 1:1 (62)
treatment and control of body weight (BW)
bleeding episodes, (2) in kg x desired
Perioperative VWF:RCo rise (%)
management of bleeding (IU/dL) x 0.5 (IU/kg
per IU/dL)
Recombinant
Vonvendi (1)On-demand treatment Give 12 to 24 n/a (63)
and control of bleeding hours prior to
episodes. (1) surgery
(2)Perioperative to allow the
management of endogenous factor
bleeding. (1) VIII levels to
(3)Routine prophylaxis to increase to at least
reduce the frequency of 30 IU/dL (minor
bleeding episodes surgery)or 60
in patients with severe IU/dL (major
Type 3 von Willebrand surgery)
disease receiving
on-demand therapy
*Plasma derived VWF/FVIII concentrates can be dosed based on the FVIII or VWF in the vial and
it is important to specify that the dosing is given based on the VWF:RCo units in the vial.
Table 3: Acquired Factor Deficiencies Associated with Bleeding
Prolonged
Normal aPTT
Prolonged aPTT & PT Prolonged aPTT, nl PT PT,
& PT*
nl aPTT
Deficiency Fibrinogen FII FV(64) FX(65) FVIII FIX FXI FVII FXIII(66-68)
Pre- - DIC - Liver - Inhibitor - Amyloidosis - Inhibitor - Inhibitor - Inhibitor - Liver - Inhibitor
disposing - Liver disease disease - Topical - Liver - DIC - DIC - DIC disease - Liver disease
factors - Trauma - Sepsis bovine disease - AVWS - Liver - Liver - Sepsis - Post op
- MGUS, MM(69) - Vitamin K thrombin - Vitamin K with disease disease - Vitamin K - Cardiovascular
- Asparaginase(70) deficiency - Antibiotics deficiency reduced - Vitamin K deficiency bypass
FVIII deficiency - Vitamin K - Inflammatory
antagonist bowel disease

*Acquired platelet dysfunction from medications/exposures should also be considered when a


patient presents with new bleeding symptoms with a normal aPTT and PT.
FIGURE 1: RESPONSE TO PDVWF/FVIII CONCENTRATE (50 U/KG DOSE)
FIGURE 2: RESPONSE TO IVIG (500 MG/KG)
Figure 3: Receiving IVIG 1 gm/kg
References
1. Werner EJ, Broxson EH, Tucker EL, Giroux DS, Shults J, Abshire TC. Prevalence of von
Willebrand disease in children: a multiethnic study. J Pediatr. 1993;123(6):893-8.
2. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von
Willebrand's disease. Blood. 1987;69(2):454-9.
3. Michael Soucie J, Miller CH, Byams VR, Payne AB, Abe K, Sidonio RF, Jr., et al.
Occurrence rates of von Willebrand disease among people receiving care in specialized
treatment centres in the United States. Haemophilia. 2021;27(3):445-53.
4. Federici AB, Budde U, Rand JH. Acquired von Willebrand syndrome 2004: International
Registry--diagnosis and management from online to bedside. Hamostaseologie. 2004;24(1):50-5.
5. Alavi P, Rathod AM, Jahroudi N. Age-Associated Increase in Thrombogenicity and Its
Correlation with von Willebrand Factor. J Clin Med. 2021;10(18).
6. Albánez S, Ogiwara K, Michels A, Hopman W, Grabell J, James P, et al. Aging and ABO
blood type influence von Willebrand factor and factor VIII levels through interrelated
mechanisms. J Thromb Haemost. 2016;14(5):953-63.
7. Rydz N, Grabell J, Lillicrap D, James PD. Changes in von Willebrand factor level and von
Willebrand activity with age in type 1 von Willebrand disease. Haemophilia. 2015;21(5):636-41.
8. Borghi M, Guglielmini G, Mezzasoma AM, Falcinelli E, Bury L, Malvestiti M, et al.
Increase of von Willebrand factor with aging in type 1 von Willebrand disease: fact or fiction?
Haematologica. 2017;102(11):e431-e3.
9. Sanders YV, Giezenaar MA, Laros-van Gorkom BA, Meijer K, van der Bom JG, Cnossen
MH, et al. von Willebrand disease and aging: an evolving phenotype. J Thromb Haemost.
2014;12(7):1066-75.
10. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, et al. A
quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a
multicenter European study (MCMDM-1 VWD). J Thromb Haemost. 2006;4(4):766-73.
11. Atiq F, Meijer K, Eikenboom J, Fijnvandraat K, Mauser-Bunschoten EP, van Galen KPM,
et al. Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the
age-related increase of VWF in von Willebrand disease. Br J Haematol. 2018;182(1):93-105.
12. Flood VH, Christopherson PA, Gill JC, Friedman KD, Haberichter SL, Bellissimo DB, et al.
Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the
United States. Blood. 2016;127(20):2481-8.
13. O'Brien JR, Green PJ, Salmon G, Weir P, Colin-Jones D, Arnold M, et al. Desmopressin
and myocardial infarction. Lancet. 1989;1(8639):664-5.
14. Lowe GD. Desmopressin and myocardial infarction. Lancet. 1989;1(8643):895-6.
15. Bond L, Bevan D. Myocardial infarction in a patient with hemophilia treated with DDAVP.
N Engl J Med. 1988;318(2):121.
16. Feldman EA, Meola G, Zyck S, Miller CD, Krishnamurthy S, Cwikla GM, et al.
Retrospective Assessment of Desmopressin Effectiveness and Safety in Patients With
Antiplatelet-Associated Intracranial Hemorrhage. Crit Care Med. 2019;47(12):1759-65.
17. Gunther M, Witenko CJ, Prust M, Salerno D, Berger K. The Safety and Efficacy of
Desmopressin in Patients With Intracranial Hemorrhage and a History of Alcohol Use. J
Intensive Care Med. 2022;37(6):825-32.
18. Gayet-Ageron A, Prieto-Merino D, Ker K, Shakur H, Ageron FX, Roberts I. Effect of
treatment delay on the effectiveness and safety of antifibrinolytics in acute severe
haemorrhage: a meta-analysis of individual patient-level data from 40 138 bleeding patients.
Lancet. 2018;391(10116):125-32.
19. Nikolaou VS, Masouros P, Floros T, Chronopoulos E, Skertsou M, Babis GC. Single dose of
tranexamic acid effectively reduces blood loss and transfusion rates in elderly patients
undergoing surgery for hip fracture: a randomized controlled trial. Bone Joint J. 2021;103-
b(3):442-8.
20. Porter SB, Spaulding AC, Duncan CM, Wilke BK, Pagnano MW, Abdel MP. Tranexamic
Acid Was Not Associated with Increased Complications in High-Risk Patients with Hip Fracture
Undergoing Arthroplasty. J Bone Joint Surg Am. 2021;103(20):1880-9.
21. Poeran J, Chan JJ, Zubizarreta N, Mazumdar M, Galatz LM, Moucha CS. Safety of
Tranexamic Acid in Hip and Knee Arthroplasty in High-risk Patients. Anesthesiology.
2021;135(1):57-68.
22. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T, et al. Tranexamic Acid in
Patients Undergoing Coronary-Artery Surgery. N Engl J Med. 2017;376(2):136-48.
23. Chornenki NLJ, Um KJ, Mendoza PA, Samienezhad A, Swarup V, Chai-Adisaksopha C, et
al. Risk of venous and arterial thrombosis in non-surgical patients receiving systemic tranexamic
acid: A systematic review and meta-analysis. Thromb Res. 2019;179:81-6.
24. Gernsheimer TB, Brown SP, Triulzi DJ, Key NS, El Kassar N, Herren H, et al. Prophylactic
tranexamic acid in patients with hematologic malignancy: a placebo-controlled, randomized
clinical trial. Blood. 2022;140(11):1254-62.
25. Connell NT, Flood VH, Brignardello-Petersen R, Abdul-Kadir R, Arapshian A, Couper S, et
al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood
Adv. 2021;5(1):301-25.
26. James PD, Connell NT, Ameer B, Di Paola J, Eikenboom J, Giraud N, et al. ASH ISTH NHF
WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv. 2021;5(1):280-300.
27. Mumford AD, O'Donnell J, Gillmore JD, Manning RA, Hawkins PN, Laffan M. Bleeding
symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis. Br J Haematol.
2000;110(2):454-60.
28. Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, et al. Acquired
von Willebrand syndrome: data from an international registry. Thromb Haemost.
2000;84(2):345-9.
29. Horiuchi H, Doman T, Kokame K, Saiki Y, Matsumoto M. Acquired von Willebrand
Syndrome Associated with Cardiovascular Diseases. J Atheroscler Thromb. 2019;26(4):303-14.
30. Warkentin TE, Moore JC, Anand SS, Lonn EM, Morgan DG. Gastrointestinal bleeding,
angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfus Med
Rev. 2003;17(4):272-86.
31. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired
von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance:
comparison of three different therapeutic approaches. Blood. 1998;92(8):2707-11.
32. Lavin M, Ryan K, White B, Byrne M, O'Connell NM, O'Donnell JS. A role for intravenous
immunoglobulin in the treatment of Acquired Von Willebrand Syndrome associated with IgM
gammopathy. Haemophilia. 2018;24(1):e22-e5.
33. Engelen ET, van Galen KP, Schutgens RE. Thalidomide for treatment of gastrointestinal
bleedings due to angiodysplasia: a case report in acquired von Willebrand syndrome and review
of the literature. Haemophilia. 2015;21(4):419-29.
34. Green A, Shen YP, Nelson AT, Sarode R, Ibrahim IF, Cao J, et al. Successful use of
lenalidomide to treat refractory acquired von Willebrand disease associated with monoclonal
gammopathy. Ann Hematol. 2022:1-5.
35. Mazoyer E, Fain O, Dhote R, Laurian Y. Is rituximab effective in acquired von Willebrand
syndrome? Br J Haematol. 2009;144(6):967-8.
36. Hawken J, Knott A, Alsakkaf W, Clark A, Fayyaz F. Rituximab to the rescue: novel therapy
for chronic gastrointestinal bleeding due to angiodysplasia and acquired von Willebrand
syndrome. Frontline Gastroenterol. 2019;10(4):434-7.
37. Ammann EM, Haskins CB, Fillman KM, Ritter RL, Gu X, Winiecki SK, et al. Intravenous
immune globulin and thromboembolic adverse events: A systematic review and meta-analysis
of RCTs. Am J Hematol. 2016;91(6):594-605.
38. Daniel GW, Menis M, Sridhar G, Scott D, Wallace AE, Ovanesov MV, et al. Immune
globulins and thrombotic adverse events as recorded in a large administrative database in 2008
through 2010. Transfusion. 2012;52(10):2113-21.
39. Kapoor M, Hunt I, Spillane J, Bonnett LJ, Hutton EJ, McFadyen J, et al. IVIg-exposure and
thromboembolic event risk: findings from the UK Biobank. J Neurol Neurosurg Psychiatry.
2022;93(8):876-85.
40. Guo Y, Tian X, Wang X, Xiao Z. Adverse Effects of Immunoglobulin Therapy. Front
Immunol. 2018;9:1299.
41. Drelich DA, Bray PF, Herman JH. Immunoglobulin therapy and thrombosis: coincidence
or causation? Transfusion. 2012;52(10):2075-7.
42. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal FR. High levels of
coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med. 2000;342(10):696-
701.
43. Cheng MJ, Christmas C. Special considerations with the use of intravenous
immunoglobulin in older persons. Drugs Aging. 2011;28(9):729-36.
44. Seaman CD, Yabes J, Comer DM, Ragni MV. Does deficiency of von Willebrand factor
protect against cardiovascular disease? Analysis of a national discharge register. J Thromb
Haemost. 2015;13(11):1999-2003.
45. Hassan SA, Amer S, Qureshi W, Alirhayim Z, Kuriakose P. Treating symptomatic coronary
artery disease in patients with Von Willebrand disease. Hematol Oncol Stem Cell Ther.
2013;6(3-4):101-4.
46. Balleisen L, Bailey J, Epping PH, Schulte H, van de Loo J. Epidemiological study on factor
VII, factor VIII and fibrinogen in an industrial population: I. Baseline data on the relation to age,
gender, body-weight, smoking, alcohol, pill-using, and menopause. Thromb Haemost.
1985;54(2):475-9.
47. Favaloro EJ, Franchini M, Lippi G. Aging hemostasis: changes to laboratory markers of
hemostasis as we age - a narrative review. Semin Thromb Hemost. 2014;40(6):621-33.
48. Favaloro EJ, Soltani S, McDonald J, Grezchnik E, Easton L. Cross-laboratory audit of
normal reference ranges and assessment of ABO blood group, gender and age on detected
levels of plasma coagulation factors. Blood Coagul Fibrinolysis. 2005;16(8):597-605.
49. Ariëns RA, Kohler HP, Mansfield MW, Grant PJ. Subunit antigen and activity levels of
blood coagulation factor XIII in healthy individuals. Relation to sex, age, smoking, and
hypertension. Arterioscler Thromb Vasc Biol. 1999;19(8):2012-6.
50. Kalot MA, Husainat N, El Alayli A, Abughanimeh O, Diab O, Tayiem S, et al. von
Willebrand factor levels in the diagnosis of von Willebrand disease: a systematic review and
meta-analysis. Blood Adv. 2022;6(1):62-71.
51. Miletich J, Sherman L, Broze G, Jr. Absence of thrombosis in subjects with heterozygous
protein C deficiency. N Engl J Med. 1987;317(16):991-6.
52. Boerger LM, Morris PC, Thurnau GR, Esmon CT, Comp PC. Oral contraceptives and
gender affect protein S status. Blood. 1987;69(2):692-4.
53. MacCallum PK, Cooper JA, Martin J, Howarth DJ, Meade TW, Miller GJ. Associations of
protein C and protein S with serum lipid concentrations. Br J Haematol. 1998;102(2):609-15.
54. Yamamoto K, Takeshita K, Kojima T, Takamatsu J, Saito H. Aging and plasminogen
activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders
in the elderly. Cardiovasc Res. 2005;66(2):276-85.
55. Lippi G, Favaloro EJ, Cervellin G. A review of the value of D-dimer testing for prediction
of recurrent venous thromboembolism with increasing age. Semin Thromb Hemost.
2014;40(6):634-9.
56. Segal JB, Moliterno AR. Platelet counts differ by sex, ethnicity, and age in the United
States. Ann Epidemiol. 2006;16(2):123-30.
57. Le Blanc J, Lordkipanidzé M. Platelet Function in Aging. Front Cardiovasc Med.
2019;6:109.
58. Grifols. Properties of treatment options for
von Willebrand disease (VWD)
https://www.alphanate.com/documents/729928/730168/Alphanate+Product+Properties+Char
t+Patient.pdf/490e3dcd-c54b-4a08-80ac-b00cf69ddc7d?t=15145388630002017 [
59. Grifols. Prescribing Information
https://www.alphanate.com/documents/729928/730168/Alphanate+PI_3057619_8.5x11_226
68_Secured.pdf/3e2c7c1d-62f7-66c4-e98b-f00391adf708?t=16399954777782021 [
60. Behring C. Dosing Overview https://www.humate-p.com/hcp/about-humate-
p/dosing#:~:text=VWF%3ARCo%20and%20FVIII%20content,raising%20FVIII%20to%20supernor
mal%20levels.2022 [
61. Behring C. Prescribing Information https://labeling.cslbehring.com/PI/US/Humate-
P/EN/Humate-P-Prescribing-Information.pdf: 2020; [
62. Octapharma. Prescribing Information https://wilateusa.com/hcp/wp-
content/uploads/sites/2/2021/11/wilate-full-prescribing-information.pdf2020 [
63. Baxalta. Prescribing Information https://www.fda.gov/media/94863/download2015
[updated 2021.
64. Huang JN, Koerper MA. Factor V deficiency: a concise review. Haemophilia.
2008;14(6):1164-9.
65. Choufani EB, Sanchorawala V, Ernst T, Quillen K, Skinner M, Wright DG, et al. Acquired
factor X deficiency in patients with amyloid light-chain amyloidosis: incidence, bleeding
manifestations, and response to high-dose chemotherapy. Blood. 2001;97(6):1885-7.
66. Chuliber FA, Schutz NP, Viñuales ES, Penchasky DL, Otero V, Villagra Iturre MJ, et al.
Nonimmune-acquired factor XIII deficiency: a cause of high volume and delayed postoperative
hemorrhage. Blood Coagul Fibrinolysis. 2020;31(8):511-6.
67. Biswas A, Ivaskevicius V, Thomas A, Oldenburg J. Coagulation factor XIII deficiency.
Diagnosis, prevalence and management of inherited and acquired forms. Hamostaseologie.
2014;34(2):160-6.
68. Ichinose A. Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13
antibodies: A summary of 93 patients. Blood Rev. 2017;31(1):37-45.
69. Dear A, Brennan SO, Sheat MJ, Faed JM, George PM. Acquired dysfibrinogenemia
caused by monoclonal production of immunoglobulin lambda light chain. Haematologica.
2007;92(11):e111-7.
70. Gralnick HR, Henderson E. Hypofibrinogenemia and coagulation factor deficiencies with
L-asparaginase treatment. Cancer. 1971;27(6):1313-20.
FIGURE 1: RESPONSE TO
PDVWF/FVIII CONCENTRATE
(50 U/KG DOSE)
VWF:RCo VWF:Ag FVIII

50
40
30

IU/DL
20
10
0
PRE 30 MIN 1 HOUR 4 HOURS
POST POST POST
FIGURE 2: RESPONSE TO IVIG
(500 MG/KG)
VWF:RCo VWF:Ag FVIII

60
50
40
30

IU/DL
20
10
0
PRE DAY 1 DAY 3 DAY 7
Figure 3: Receiving IVIG 1 gm/kg
250

200

150

100

50

0
3/12/2019 4/12/2019 5/12/2019 6/12/2019 7/12/2019 8/12/2019 9/12/2019 10/12/2019 11/12/2019

VWF:RCo VWF:Ag FVIII

You might also like

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy